Costs and Effectiveness of Neonatal Male Circumcision | Infectious Diseases | JAMA Pediatrics | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.207.129.82. Please contact the publisher to request reinstatement.
Article
Comparative Effectiveness Research
Oct 2012

Costs and Effectiveness of Neonatal Male Circumcision

Author Affiliations

Author Affiliations: Departments of Pathology (Ms Kacker and Dr Tobian) and Medicine and Emergency Medicine (Dr Gaydos), School of Medicine, and Departments of Health Policy and Management (Dr Frick) and Epidemiology and Population, Family, and Reproductive Health (Dr Gaydos), Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Arch Pediatr Adolesc Med. 2012;166(10):910-918. doi:10.1001/archpediatrics.2012.1440
Abstract

Objective To evaluate the expected change in the prevalence of male circumcision (MC)–reduced infections and resulting health care costs associated with continued decreases in MC rates. During the past 20 years, MC rates have declined from 79% to 55%, alongside reduced insurance coverage.

Design We used Markov-based Monte Carlo simulations to track men and women throughout their lifetimes as they experienced MC procedure-related events and MC-reduced infections and accumulated associated costs. One-way and probabilistic sensitivity analyses were used to evaluate the impact of uncertainty.

Setting United States.

Participants Birth cohort of men and women.

Intervention Decreased MC rates (10% reflects the MC rate in Europe, where insurance coverage is limited).

Outcomes Measured Lifetime direct medical cost (2011 US$) and prevalence of MC-reduced infections.

Results Reducing the MC rate to 10% will increase lifetime health care costs by $407 per male and $43 per female. Net expenditure per annual birth cohort (including procedure and complication costs) is expected to increase by $505 million, reflecting an increase of $313 per forgone MC. Over 10 annual cohorts, net present value of additional costs would exceed $4.4 billion. Lifetime prevalence of human immunodeficiency virus infection among males is expected to increase by 12.2% (4843 cases), high- and low-risk human papillomavirus by 29.1% (57 124 cases), herpes simplex virus type 2 by 19.8% (124 767 cases), and infant urinary tract infections by 211.8% (26 876 cases). Among females, lifetime prevalence of bacterial vaginosis is expected to increase by 51.2% (538 865 cases), trichomoniasis by 51.2% (64 585 cases), high-risk human papillomavirus by 18.3% (33 148 cases), and low-risk human papillomavirus by 12.9% (25 837 cases). Increased prevalence of human immunodeficiency virus infection among males represents 78.9% of increased expenses.

Conclusion Continued decreases in MC rates are associated with increased infection prevalence, thereby increasing medical expenditures for men and women.

×